Browsing Tag
oncology supportive care
3 posts
Can oral NMDA blockers like Ketamir-2 disrupt current off-label CIPN treatments?
Find out how MIRA Pharmaceuticals’ Ketamir-2 aims to disrupt CIPN care with oral NMDA therapy as the company targets Fast Track and prepares for Phase 2a trials.
Hoth Therapeutics (NASDAQ: HOTH) stakes claim on emerging oncodermatology space with dual patent filings for HT-001
Hoth Therapeutics files dual patents for HT-001 in oncology dermatology. Find out what this means for its IP strategy and cancer care positioning.
RedHill Biopharma secures $60m licensing agreement with Hyloris for global commercialization of RHB-102
RedHill Biopharma Ltd. has entered into an exclusive licensing agreement with Hyloris Pharmaceuticals SA, granting the Belgian company…